^
Association details:
| Biomarker: | STK11 mutation + KEAP1 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | hydroxyureamethylacylfulvene (STAR-001) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer
Published date:
08/08/2023
Excerpt:
LP-184 treatment at 5 mg/kg i.p. twice weekly for 2 weeks resulted in 108.5% tumor growth inhibition in H460 xenograft model of lung cancer harboring KEAP1/STK11 co-mutations.
